In papillary thyroid cancer, the incidence of BRAF mutations ranges from 45% to 50.9%, with dabrafenib and trametinib combination therapy yielding an OS of 14.5 months, PFS of 6.7 months, and ORR of 56%. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.